B2BROKER Introduces PrimeXM XCore Support & Maintenance Services for Brokers
19.2.2025 12:56:00 CET | Business Wire | Press release
B2BROKER has announced the launch of its PrimeXM XCore support and maintenance services, expanding its suite of technology solutions for brokers and financial institutions. This new solution complements the company’s existing support offerings for trading platforms, including cTrader, MT4, and MT5.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250217935952/en/
B2BROKER's PrimeXM XCore Service provides complete support to manage all technical aspects, including setup and ongoing maintenance, of the PrimeXM XCore server. (Graphic: Business Wire)
PrimeXM XCore in the Trading Industry
PrimeXM’s XCore is a widely used trading and aggregation engine, serving over 250 financial institutions worldwide. It provides ultra-low latency order execution, risk management capabilities, and advanced reporting tools while supporting multi-asset trading across multiple venues.
As a key component in modern brokerage infrastructure, XCore offers brokers improved liquidity access and streamlined execution. However, maintaining and managing the system can be resource-intensive, often requiring the recruitment and training of specialised personnel. Establishing an in-house team to operate XCore typically involves significant time and financial investment.
B2BROKER’s Managed PrimeXM XCore Services
Recognising the operational challenges, B2BROKER has introduced a fully managed PrimeXM XCore service designed to reduce brokers' workloads.
The new service ensures that industry professionals handle all technical aspects of the system, from setup to ongoing maintenance. This allows brokers to focus on business development and client service.
Additionally, B2BROKER introduces a dedicated audit service for clients with an existing PrimeXM server. This service involves a thorough assessment of the setup and detailed recommendations to optimise system performance and ensure a seamless transition under the company’s maintenance.
Arthur Azizov, CEO and Founder of B2BROKER, says:
"We provide comprehensive support to manage all technical aspects of PrimeXM XCore, including setup, ongoing maintenance, and day-to-day operations. No matter the number or type of liquidity providers a broker works with, B2BROKER guarantees seamless trading operations."
Clive Diethelm, CEO and Founder of PrimeXM, comments:
"By collaborating with B2BROKER, we aim to enhance our offerings with flexible support models, ensuring clients can choose solutions that best fit their requirements."
Key Features of the Service
The service package provided by B2BROKER includes:
- Comprehensive System Configuration – Full setup of trading infrastructure, including instruments, asset classes, and user access management.
- Secure Connectivity – Secure and stable integration with liquidity providers and trading venues to ensure seamless execution.
- Customisable Trading Parameters – Adaptation of trading and routing rules to align with each broker’s operational model.
- Continuous Monitoring & Support – 24/7 system oversight to maintain stability and rapid issue resolution.
- Automated Performance Reports – Generation of daily and monthly reports offering insights into system performance and trading efficiency.
Summary
By introducing this service, B2BROKER aims to simplify technical management for brokers relying on PrimeXM XCore. The fully managed approach reduces operational complexities, minimises costs associated with in-house maintenance, and ensures uninterrupted trading operations.
For brokers seeking a reliable and efficient way to manage their PrimeXM XCore infrastructure, B2BROKER’s new service provides a structured solution backed by industry expertise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250217935952/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom